



Takeda's Approach to Key Sustainability Topics

Water Stewardship

Water is a critical resource for Takeda and for the communities in which we operate. Without it, we cannot achieve our vision of discovering and delivering life-transforming treatments, or meet our commitments to patients, people and the planet. Takeda is taking action to minimize our water footprint and ensure that our operations do not negatively impact local water resources. Accordingly, we have committed to a 5% reduction in water withdrawal by FY2025 (relative to FY2019 levels), and we are achieving these reductions through investments in water efficiency projects and through the adoption of water treatment and reuse technologies. Takeda takes a context-based approach to water stewardship where we seek to understand and address the specific burdens affecting water sources in the watersheds where we operate, prioritizing and focusing efforts and resources to locations identified as highly water-stressed.

Plastics

Plastics are currently necessary for the manufacture, distribution, and administration of Takeda's medicinal products. As a key raw material, plastics ensure patient safety and product quality while offering an inexpensive, effective option for reducing the overall environmental impact compared to alternatives (e.g., glass or stainless steel, when considering a full life cycle assessment). However, Takeda recognizes that plastics can have negative impacts on our planet. Plastics are primarily made from non-renewable resources, and their end-of-life impacts can be challenging. While some recycling of plastics occurs, much more makes its way to landfills or is incinerated, and may be released to the environment, especially in regions without good waste handling practices. Takeda uses lifecycle thinking and the full value chain perspective to assess plastics used for manufacturing, packaging and products. We also carefully manage wastes from our own facilities, and strive to effectively recycle plastics. Takeda has committed to achieve zero waste to landfill status by 2030 for all major locations.

Biodiversity

Takeda recognizes that biodiversity loss could have consequences for human health and the pharmaceutical industry. We acknowledge our role in the preservation and restoration of nature and support the need to stop and reverse the decline in global biodiversity. Takeda has long-recognized the value of medicinal plants and established a large garden in Kyoto, Japan in 1933. Home to more than 3000 species, the garden has evolved to

become an institute for collecting, preserving, and cultivating herbal plants used for educational and research purposes. Biodiversity is an emerging element of Takeda's sustainability program. We recently launched an effort to screen all sites for material biodiversity impacts, and we are continuing to expand the scope of the assessment. Some of our manufacturing sites help provide habitats to native and endangered or rare species (e.g. natural ponds, beehives, planting trees or permaculture garden).

Pharmaceuticals in the Environment

Takeda recognizes that active pharmaceuticals in the environment can have negative ecological impacts. The presence of pharmaceuticals in the environment is reported to be driven primarily through residues from patient use and excretion, to a lesser extent through the improper disposal of unused or expired medications, and to an even lesser extent through emissions from drug manufacturing processes. Because of the limited ability to directly or completely control the most significant emission pathways, releases of pharmaceuticals into the environment cannot be completely avoided with currently available technologies and practices. However, Takeda believes that meaningful steps can be taken within our control to ensure that emissions and impacts are minimized. Accordingly, we assess the environmental risk of our active pharmaceuticals in accordance with pharmaceutical drug regulatory approval processes and manage the environmental emissions of our manufacturing.

Eco-design

In 2021, Takeda established a comprehensive Sustainability by Design Program to integrate environment and human health considerations into our product development process. Takeda is implementing sustainable design and material selection processes into drug development for all therapies with the objective to minimize the environmental impact of Takeda's products and manufacturing processes, when possible. This effort is guided by insights from life cycle assessments, management best practices, and evolving regulatory requirements. Beyond the product itself, Takeda also applies eco-design concepts to reduce the environmental footprint of our packaging and medical devices, and to improve their recyclability and re-use.

March 2022